BCR and neoplasm: XPO1 inhibition traps BCR–ABL in the nucleus, re-sensitizing leukemia cells to the BCR–ABL inhibitor imatinib and resulting in a substantial reduction in tumor cell proliferative potential with limited toxicity to normal myeloid precursors [36].